MA44110A - Polythérapie - Google Patents

Polythérapie

Info

Publication number
MA44110A
MA44110A MA044110A MA44110A MA44110A MA 44110 A MA44110 A MA 44110A MA 044110 A MA044110 A MA 044110A MA 44110 A MA44110 A MA 44110A MA 44110 A MA44110 A MA 44110A
Authority
MA
Morocco
Prior art keywords
cancer
alaninyl
benzoxy
phenyl
phosphate
Prior art date
Application number
MA044110A
Other languages
English (en)
Other versions
MA44110B1 (fr
Inventor
Hugh Griffith
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Priority claimed from EP16820005.3A external-priority patent/EP3393478B1/fr
Publication of MA44110A publication Critical patent/MA44110A/fr
Publication of MA44110B1 publication Critical patent/MA44110B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne une association de gemcitabine- [phényl-benzoxy-l-alaninyl)]-phosphate (nom chimique: 2 '-désoxy -2 ', 2 '-difluoro-d-cytidine -5 '-o- [phényl (benzoxy-l-alaninyl) ] phosphate) (nuc -1031) et un agent anticancéreux à base de platine choisi parmi le cisplatine, le picoplatine, le lipoplatine et le triplatine. Les combinaisons sont utiles dans le traitement du cancer et en particulier le cancer de la vésicule et des voies biliaires et le cancer de la vessie.
MA44110A 2015-12-23 2016-12-21 Polythérapie MA44110B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2015/054158 WO2017109444A1 (fr) 2015-12-23 2015-12-23 Traitement combiné
EP16820005.3A EP3393478B1 (fr) 2015-12-23 2016-12-21 Polythérapie
PCT/GB2016/054018 WO2017109486A1 (fr) 2015-12-23 2016-12-21 Polythérapie

Publications (2)

Publication Number Publication Date
MA44110A true MA44110A (fr) 2018-10-31
MA44110B1 MA44110B1 (fr) 2020-03-31

Family

ID=55069010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44110A MA44110B1 (fr) 2015-12-23 2016-12-21 Polythérapie

Country Status (6)

Country Link
US (1) US20190381084A1 (fr)
KR (1) KR102566461B1 (fr)
AU (1) AU2015418015B2 (fr)
CA (1) CA3008769A1 (fr)
MA (1) MA44110B1 (fr)
WO (1) WO2017109444A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
WO2015198059A1 (fr) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprenant un promédicament de gemcitabine
EP3160978B1 (fr) 2014-06-25 2020-07-29 NuCana plc Prodrogues de gemcitabine
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
RS62593B1 (sr) 2015-12-11 2021-12-31 NuCana plc Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
IL265044B2 (en) 2016-08-31 2025-02-01 Fujifilm Corp An antitumor preparation containing the substances nab-paclitaxel and 1-(2-deoxy-2-fluoro-4-thio-D-beta-arabinofurnosyl)cytosine, a kit containing these substances and their uses
GB201713914D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy
WO2022098704A1 (fr) * 2020-11-03 2022-05-12 Rafael Pharmaceuticals, Inc. Méthodes et compositions thérapeutiques pour traiter le cancer du tractus biliaire en utilisant du devimistat
EP4704902A1 (fr) * 2023-05-05 2026-03-11 Purdue Research Foundation Polythérapie pour le traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
SMT201800303T1 (it) * 2015-05-14 2018-07-17 NuCana plc Trattamenti per il cancro

Also Published As

Publication number Publication date
CA3008769A1 (fr) 2017-06-29
US20190381084A1 (en) 2019-12-19
KR102566461B1 (ko) 2023-08-14
WO2017109444A1 (fr) 2017-06-29
KR20180096697A (ko) 2018-08-29
AU2015418015B2 (en) 2021-12-09
AU2015418015A1 (en) 2018-07-05
MA44110B1 (fr) 2020-03-31

Similar Documents

Publication Publication Date Title
MA44110A (fr) Polythérapie
PH12018501339A1 (en) Combination therapy
MX385837B (es) Terapia de combinacion.
MA43335A (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
CY1120536T1 (el) Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου
TW200716141A (en) Compositions and methods for treatment for neoplasms
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MA45809B1 (fr) Promédicaments de pth
EP4393495A3 (fr) Compositions d'arni de ligand 1 de mort cellulaire programmée 1 (pd-l1) et leurs procédés d'utilisation
BR112016013547A2 (pt) Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
MX2015011752A (es) Metodos para tratar cancer de pulmon.
MA38959A1 (fr) Modulateurs du facteur b du complément
MA52063B1 (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
BR112012024442A2 (pt) métodos de tratamento de câncer
EP3626832A3 (fr) Procédé d'identification et de traitement d'une personne présentant une prédisposition à ou souffrant d'une maladie cardio-métabolique
CY1117722T1 (el) Βελτιωμενη αγωγη του πολλαπλου μυελωματος
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
EA201892803A1 (ru) Противоопухолевая терапия
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
EA201890068A1 (ru) Частицы диметилфумарата и фармацевтические композиции на их основе
MX2020013120A (es) Tratamiento terapéutico de cánceres de microsatélites inestables.
EP3736022A3 (fr) Traitement et diagnostic du cancer du colon